Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoids

            Therapeutic Area: Dermatology Product Name: JW-100

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2021

            Details:

            Jupiter Wellness commenced patient enrollment for skin cancer. Jupiter's JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pyrilutamide

            Therapeutic Area: Dermatology Product Name: KX-826

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 16, 2021

            Details:

            The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GT20029

            Therapeutic Area: Dermatology Product Name: GT20029

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 02, 2021

            Details:

            GT20029 is a topical androgen receptor degrader developed by using Kintor's in-house PROTAC platform. PROTAC is a small molecule composed of a recruiting element for a protein of interest; an E3 ubiquitin ligase recruiting element; and a linker bounding (i) and (ii).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NM26-2198

            Therapeutic Area: Dermatology Product Name: NM26-2198

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kaken Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 13, 2021

            Details:

            Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KT-474

            Therapeutic Area: Dermatology Product Name: KT-474

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 12, 2020

            Details:

            Kymera Therapeutics will present poster titled "Targeted Protein Degradation Beyond Oncology,” and share recent data related to the company’s IRAK4 program including findings from the company’s non-interventional trial in hidradenitis suppurativa (HS) patients.